GUIDELINE FOR PREPARATION AND PUBLICATION OF PUBLIC ASSESSMENT REPORTS FOR APPROVED MEDICINES
GUIDELINE FOR PREPARATION AND PUBLICATION OF PUBLIC ASSESSMENT REPORTS FOR APPROVED MEDICINES
Rosutrox 5 mg, 10 mg, 20 mg and 40 mg film coated tablets_SUMMARY OF PRODUCT CHARACTERISTICS
Rosutrox 5 mg, 10 mg, 20 mg and 40 mg film coated tablets_SUMMARY OF PRODUCT CHARACTERISTICS
Rosutrox 5 mg, 10 mg, 20 mg and 40 mg film coated tablets _ Public assessment summary report_Package label
Rosutrox 5 mg, 10 mg, 20 mg and 40 mg film coated tablets _ Public assessment summary report_Package label
PASURTA (erenumab) 140 mg per mL _ SUMMARY OF PRODUCT CHARACTERISTICS
PASURTA (erenumab) 140 mg per mL _ SUMMARY OF PRODUCT CHARACTERISTICS
PASURTA (erenumab) 140 mg per mL _ Public assessment summary report_Package label
PASURTA (erenumab) 140 mg per mL _ Public assessment summary report_Package label
Magnesium sulfate-Kalceks 500 mg per ml solution for injection_SUMMARY OF PRODUCT CHARACTERISTICS
Magnesium sulfate-Kalceks 500 mg per ml solution for injection_SUMMARY OF PRODUCT CHARACTERISTICS
OCTANATE 500 and OCTANATE 1000 _SUMMARY OF PRODUCT CHARACTERISTICS
OCTANATE 500 and OCTANATE 1000 _SUMMARY OF PRODUCT CHARACTERISTICS
OCTANATE 500 and OCTANATE 1000 _ Public assessment summary report
OCTANATE 500 and OCTANATE 1000 _ Public assessment summary report
Utrogestan Vaginal 100 mg and 200 mg Soft capsules _ Public assessment summary report_Package label
Utrogestan Vaginal 100 mg and 200 mg Soft capsules _ Public assessment summary report_Package label
Utrogestan Vaginal 100 mg and 200 mg Soft capsules_SUMMARY OF PRODUCT CHARACTERISTICS
Utrogestan Vaginal 100 mg and 200 mg Soft capsules_SUMMARY OF PRODUCT CHARACTERISTICS